Abstract
WE write to raise awareness of potential adverse effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which are increasingly being used in the treatment of horses with equine metabolic syndrome (EMS), refractory hyperinsulinaemia and associated laminitis.
Original language | English |
---|---|
Pages (from-to) | 253-254 |
Number of pages | 2 |
Journal | Veterinary Record |
Volume | 195 |
Issue number | 6 |
DOIs | |
Publication status | E-pub ahead of print - 20 Sept 2024 |